New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
16:31 EDTDEPODepomed files patent infringement suit against Purdue Pharma
Depomed disclosed in a regulatory filing that on January 29, Depomed filed a complaint in the United States District Court for the District of New Jersey against Purdue Pharma and affiliated companies for infringement of U.S. Patent Nos. 6,340,475; 6,635,280; and 6,723,340. The complaint alleges infringement of the Depomed patents arising from Purdue’s commercialization of OxyContin in the United States. The Depomed patents relate to Depomed’s Acuform drug delivery technology. U.S. Patent Nos. 6,340,475 and 6,635,280 will expire in 2016, and U.S. Patent No. 6,723,340 will expire in 2021.
News For DEPO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 20, 2015
09:18 EDTDEPOJohnson & Johnson CEO says core businesses 'strong'
Johnson & Johnson (JNJ) providing sustainable, high quality healthcare "one of society's greatest challenges." Says core businesses "strong," positioned to continue expanding their leadership positions. CEO Alex Gorsky says company is changing the way it interacts with customers, evolving to be more "effective," "efficient." Says U.S. OTC consent decree requirements completed. Says in the process of developing a China lung center. Says still plans to take $1B out of P&L in next three years. Says aims to bring Ebola vaccine to market "as fast as possible." Says "well-positioned" for long-term. Says currency headwinds have increased "quite substantially," negatively impacting sales, earnings to greater extent than company had anticipated. Sees Depomed (DEPO) transaction closing in Q2. Expects R&D tax credit will be renewed in 2015. If R&D tax credit is approved, sees effective tax rate for 2015 of approx. 20%-21%. Sees operational sales growth for 2015 approx. 6%. Says Wall Street forecasts may not adequately reflect likely negative impact in 2015 of foreign exchange. Sees FY15 operational sales growth 1%-2% in constant currency. Comments made on the Q4 earnings conference call.
January 16, 2015
16:29 EDTDEPOOn The Fly: Closing Wrap
Subscribe for More Information
12:43 EDTDEPOOn The Fly: Midday Wrap
Subscribe for More Information
09:12 EDTDEPOOn The Fly: Pre-market Movers
Subscribe for More Information
09:09 EDTDEPODepomed acquisition 'compelling,' says JMP Securities
Subscribe for More Information
08:58 EDTDEPORoth Capital says Depomed now leading pain company, ups to Buy
Roth Capital upgraded Depomed (DEPO) to Buy from Neutral saying the Nucynta transaction transforms the company into a "leading pain company now with critical mass." Roth raised its price target for shares to $25. Depomed last night announced that it acquired the U.S. rights to the Nucyntafranchise for $1.05B from Johnson & Johnson's (JNJ) Jansen unit. Depomed is trading up 9% in pre-market trading to $19.19.
07:49 EDTDEPODepomed upgraded to Buy from Neutral at Roth Capital
Subscribe for More Information
January 15, 2015
18:28 EDTDEPOOn The Fly: After Hours Movers
Subscribe for More Information
16:08 EDTDEPOJ&J unit sells U.S. Nucynta license rights to Depomed for $1.05B
Subscribe for More Information
16:08 EDTDEPODepomed to acquire U.S. rights to NUCYNTA franchise for $1.05B from Jansen
Subscribe for More Information
16:05 EDTDEPODepomed to acquire U.S. rights to NUCYNTA franchise for $1.05B from Jansen
16:01 EDTDEPODepomed trading halted, pending news

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use